Maintenance in gastric cancer: New life for an old issue?
First-line
Gastric cancer
Maintenance
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
04
08
2020
revised:
06
02
2021
accepted:
03
03
2021
pubmed:
24
3
2021
medline:
21
4
2021
entrez:
23
3
2021
Statut:
ppublish
Résumé
The interest in maintenance therapy for patients with advanced cancers has been rapidly growing. Maintenance therapy is a useful strategy that may strengthen results of induction therapy thus extending survival and preserving the quality of life (QoL) with less toxicity. Maintenance also represents a suitable setting to investigate novel agents. The value of maintenance therapy after first-line chemotherapy has been well established in several solid tumours, such as colorectal, lung, breast, and ovarian cancer in which it is largely adopted. To date, there is no established role for maintenance therapy following first-line chemotherapy for advanced gastric cancer (GC). This review summarizes the current knowledge regarding maintenance strategies in advanced GC exploring cytotoxic agents, biologic agents and immunotherapy. We also critically review new issues to optimize randomized clinical trials for maintenance therapies and suggest clinical consideration to guide a personalized approach in daily clinical practice for this setting.
Identifiants
pubmed: 33753249
pii: S1040-8428(21)00095-0
doi: 10.1016/j.critrevonc.2021.103307
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103307Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.